Substitutions at C2′ of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity

European Journal of Biochemistry

Volumn 240, Issue 2, 1996, Pages 331-335

  Gao, Yi Gui ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Anthracycline; Anticancer drug design; Covalent adduct; Dna crystallography; Drug dna complex

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CRYSTALLOGRAPHY; CYTOTOXICITY; DNA BINDING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTINEOPLASTIC; CRYSTALLOGRAPHY, X-RAY; DAUNORUBICIN; DNA; DNA ADDUCTS; DRUG DESIGN; HEXOSAMINES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; OLIGODEOXYRIBONUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029812019     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-1033.1996.0331h.x     Document Type: Article

References (4)

1. Lown, J. W. (ed.) (1988) Anthracycline and anthracenedione-based anti-cancer agents, Elsevier, Amsterdam.
2. Priebe, W. (ed.) (1995) Anthracycline antibiotics, American Chemical Society, Washington DC.
3. Wang, A. H.-J. (1992) Intercalative drug binding to DNA, Curr. Opin. Struct. Biol. 2, 361-368.
4. Priebe, W. (1995) Mechanism of action-governed design of anthracycline antibiotics: A "turn-off/tum-on" approach, Curr. Phannacent. Design 1, 51-68.